Cartesian Therapeutics (RNAC) Payables (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Payables data on file, last reported at $1.6 million in Q1 2026.

• On a quarterly basis, Payables fell 23.8% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 23.8% decrease from a year earlier, with the FY2025 full-year figure at $1.3 million, up 347.22% from the prior year.
• Payables for Q1 2026 stood at $1.6 million, up from $1.3 million in the prior quarter.
• Over the last five years, Payables for RNAC reached as high as $31.5 million in Q4 2023 and fell as low as $214000.0 in Q3 2022.
• Historically, Payables has averaged $2.9 million across 5 years, with a median of $693000.0 in 2022.
• Across the five-year window, Payables surged 9854.75% in 2023 and sank 99.08% in 2024, its largest moves.
• Year by year, Payables stood at $316000.0 in 2022, then jumped by 9854.75% to $31.5 million in 2023, then sank by 99.08% to $288000.0 in 2024, then soared by 347.22% to $1.3 million in 2025, then grew by 24.07% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $1.6 million in Q1 2026, $1.3 million in Q4 2025, and $2.2 million in Q3 2025.